Opinion statement
The treatment of acute decompensated heart failure in the presence of progressive renal dysfunction is a commonly encountered dilemma in clinical practice. Also known as cardiorenal syndrome, this complex disease state has forced researchers and clinicians to develop new treatment strategies to relieve the symptomatic congestion of heart failure while preserving renal function. Loop diuretics remain the standard of pharmacologic treatment of acute heart failure, but their effects on renal function have been called into question. The DOSE trial set out to determine optimal diuretic dosing strategies but no clear regimen was firmly established. Initial studies with vasopressin antagonists showed promise in their ability to increase urine output, provide short-term symptom relief, and correct hyponatremia while maintaining renal function. Unfortunately, the EVEREST trial did not demonstrate any benefit on long-term clinical outcomes. Adenosine antagonists also appeared to be an emerging therapeutic option, but the recently completed PROTECT trial failed to establish their role in the treatment of cardiorenal syndrome. Both nesiritide and low-dose dopamine have endured years of trials with mixed results. Most recently, findings from the ASCEND-HF trial showed that nesiritide was safe with no adverse effects on renal function or mortality and was associated with a modest improvement in dyspnea. The ongoing ROSE study, sponsored by the National Institutes of Health Heart Failure Research Network, will attempt to confirm the safety and efficacy profiles of low-dose nesiritide and dopamine, as well as clarify their roles within acute heart failure management. Despite its inherent complexities, ultrafiltration has demonstrated potential benefit in several clinical outcomes compared to traditional pharmacotherapy. The results of the CARRESS-HF trial will reveal how the use of ultrafiltration specifically applies to patients with cardiorenal syndrome. The most exciting aspects about our evolving understanding of the cardiorenal system are the innovative treatments that have emerged as a result. The creation of chimeric natriuretic peptides, targeted intra-renal pharmacotherapy, the novel use of phosphodiesterase inhibitors, and combination treatment strategies demonstrate that despite our varied success in treating cardiorenal syndrome in the past, there are highly encouraging translational therapies rapidly developing in the pipeline.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Roger VL et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.
Forman DE et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–7.
Hillege HL et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.
Ronco C et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.
Damman K et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582–8.
Mullens W et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.
Gottlieb SS et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–53.
Vogel MW, Chen HH. Novel natriuretic peptides: new compounds and new approaches. Curr Heart Fail Rep. 2011;8:22–7.
Chen HH, Burnett Jr JC. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111:406–16.
Peacock WF et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12–9.
Mullens W et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:300–6.
Salvador DR, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;CD003178.
Felker GM et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
Lemmens-Gruber R, Kamyar M. Vasopressin antagonists. Cell Mol Life Sci. 2006;63:1766–79.
Udelson JE et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–23.
Gheorghiade M et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.
Konstam MA et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–31.
Gottlieb SS. Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep. 2008;5:105–9.
Massie BM, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419–28.
Cheng JW. Nesiritide: review of clinical pharmacology and role in heart failure management. Heart Dis. 2002;4:199–203.
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.
Witteles RM et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835–40.
Riter HG et al. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47:2334–5.
Hernandez AF et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009;157:271–7.
Horowitz JD et al. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther. 2011;25:69–76.
Goldberg LI. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1989;14:S21–8.
Friedrich JO et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510–24.
Heart Failure Network: ROSE Trial. Available at https://www.hfnetwork.org/hf-trials/rose-trial. Accessed June 2011.
Udani SM, Murray PT. The use of renal replacement therapy in acute decompensated heart failure. Semin Dial. 2009;22:173–9.
Costanzo MR, et al. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail. 2010;16:277–84.
Heart Failure Network: CARRESS-HF Trial. Available at https://www.hfnetwork.org/hf-trials/carress-trial. Accessed June 2011.
Swan SK. Diuretic strategies in patients with renal failure. Drugs. 1994;48:380–5.
Paterna S et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double blind study. J Am Coll Cardiol. 2005;45:1997–2003.
Licata G et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145:459–66.
Chen HH et al. Local renal delivery of a natriuretic peptide: a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol. 2009;53:1302–8.
Teirstein PS et al. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol. 2006;97:1076–81.
Lee CY, Lieu H, Burnett Jr JC. Designer natriuretic peptides. J Investig Med. 2009;57:18–21.
Lisy O et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60–8.
Hunt PJ et al. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 1994;78:1428–35.
Lee CY, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49:668–73.
Katz SD. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail. 2003;9:9–15.
Supaporn T et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 1996;50:1718–25.
Chen HH et al. Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006;17:2742–7.
Krum H et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.
Disclosure
S. Dandamudi: none; H. Chen has received research funding from Scios Inc, Niles Therapeutics, and Anexon Inc. The Mayo Clinic and Dr. Chen have patented designer chimeric natriuretic peptides and the Mayo Clinic has licensed designer natriuretic peptides to Niles Therapeutics and Anexon Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dandamudi, S., Chen, H.H. Evolving Treatment Strategies for Management of Cardiorenal Syndrome. Curr Treat Options Cardio Med 13, 556–569 (2011). https://doi.org/10.1007/s11936-011-0148-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11936-011-0148-3